Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer

Conclusion: This first-in-human study demonstrates that 99mTc-labeled anti–PD-L1-single-domain antibody SPECT/CT imaging is safe and associated with acceptable dosimetry. Tumor uptake is readily visible against background tissues, particularly at 2 h when the T:BP ratio correlates with PD-L1 immunohistochemistry results.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research

Related Links:

Authors: Yu XJ, Chen G, Yang J, Yu GC, Zhu PF, Jiang ZK, Feng K, Lu Y, Bao B, Zhong FM Abstract Smoking is the biggest risk factor for lung cancer. Smokers have a much higher chance of developing lung tumors with a worse survival rate; however, non-smokers also develop lung tumors. A number of questions remain including the underlying difference between smoker and non-smoker lung cancer patients and the involvement of genetic and epigenetic processes in tumor development. The present study analyzed the mutation data of 100 non-small cell lung cancer (NSCLC) patients, 12 non-smokers, 48 ex-smokers and 40 smokers, fr...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
In this study, we demonstrated the effects of gefitinib, a tyrosine kinase inhibitor of EGFR, on the cellular uptake of EVs. In EGFR-mutant HCC827 non-small cell lung cancer (NSCLC) cells, which are sensitive to gefitinib, macropinocytosis was suppressed by gefitinib treatment. However, the cellular uptake of EVs was increased by gefitinib treatment, whereas that of liposomes was reduced. In accordance with the results of the cellular uptake studies, the anti-cancer activity of doxorubicin (DOX)-loaded EVs in HCC827 cells was significantly increased in the presence of gefitinib, whereas the activity of DOX-loaded liposomes...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
ConclusionsTaselisib in combination with a taxane has a challenging safety profile. Despite evidence of antitumor activity, the benefit –risk profile was deemed not advantageous. Further development is not planned.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Sun HB, Xu L, Wang ZX, Zheng Y, Zhao Y, Yin YY, Han XL, Xu ZN Abstract OBJECTIVE: To explore the influence of polyoxometalate SbW9 on proliferation and apoptosis of non-small cell lung cancer (NSCLC) cells and its mechanism. MATERIALS AND METHODS: NSCLC cell lines A549 and PC9 were treated with 50 μM polyoxometalate. Then, the proliferation of NSCLC cells was detected via 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-t tetrazolium hydroxide (XTT) assay and colony formation assay; the apoptosis of NSCLC cells was detected via flow cytometry and terminal deoxynucleotidyl transf...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: LncRNA NBR2 inhibited the progression of EMT in NSCLC by regulating the Notch1 pathway. PMID: 31599420 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: Our study indicates that CASC15 could promote metastasis and proliferation of NSCLC through sponging miR-130b-3p in vitro and in vivo, which may offer a new therapeutic intervention for NSCLC patients. PMID: 31599419 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: December 2019Source: Biomedicine &Pharmacotherapy, Volume 120Author(s): Yang Li, Yayun Wu, Qi Xia, Ya Zhao, Ruizhi Zhao, Shigui DengAbstractCisplatin (DDP) is a first-line drug for non-small cell lung cancer (NSCLC), but its efficacy and applications are constrained by intolerance and serious side effects. Platycodon grandiflorus (PG) is usually used as lung medicinal drug to enhance other drug’s effect on lung diseases. Therefore, present study aim to investigate anti-NSCLC effect of PG with DDP and mechanism involved in the combination for the first time. The results showed that compared with ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Overall survival after radiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC) continues to be far from optimal despite recent progress with the use of adjuvant immune checkpoint inhibitors, which has resulted in a 10% increase (from 56% to 66%) in the two-year overall survival (OS) rates [1,2]. Of particular interest, cardio-pulmonary dose has been found to correlate negatively with OS in various LA-NSCLC series, including RTOG 0617 [3 –8]. The primary hypothesis addressed to this correlation has been radiation-induced cardiac toxicity, and a number of studies have thereafter established an asso...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
The neoantigens found in the patients ’ tumors (non-small-cell lung cancer) which were highly dissimilar were enriched for hydrophobic sequences, and correlated with survival rates after the PD-1 checkpoint therapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | CT Scan | Immunotherapy | Liver | Lung Cancer | Non-Small Cell Lung Cancer | Nuclear Medicine | PET Scan | SPECT | Study | Urology & Nephrology